Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System
MD, MSc Scott Dryden-Peterson, BS Andy Kim, MD Arthur Y Kim, ScD Ellen C Caniglia, MD, MPH, MBA Inga T Lennes, MD, MPH Rajesh Patel, RN Lindsay Gainer, RN Lisa Dutton, RN, MSN, NP-C Elizabeth Donahue, MD Rajesh T Gandhi, MD Lindsey R Baden, MD, MPH Ann E Woolley
Annals of Internal Medicine, doi:10.7326/m22-2141
Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death among unvaccinated outpatients with early COVID-19. The clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. Objective: To assess whether nirmatrelvir plus ritonavir reduces risk for hospitalization or death among outpatients with early COVID-19 in the setting of prevalent SARS-CoV-2 immunity and immune-evasive SARS-CoV-2 lineages. Design: Population-based cohort study analyzed to emulate a clinical trial using inverse probability-weighted models to account for anticipated bias in treatment. Setting: A large health care system providing care for 1.5 million patients in Massachusetts and New Hampshire during the Omicron wave (1 January to 17 July 2022). Patients: 44 551 nonhospitalized adults (90.3% with ≥3 vaccine doses) aged 50 years or older with COVID-19 and no contraindications for nirmatrelvir plus ritonavir.
Measurements: The primary outcome was a composite of hospitalization within 14 days or death within 28 days of a COVID-19 diagnosis. Results: During the study period, 12 541 (28.1%) patients were prescribed nirmatrelvir plus ritonavir, and 32 010 (71.9%) were not. Patients prescribed nirmatrelvir plus ritonavir were more likely to be older, have more comorbidities, and be vaccinated. The composite outcome of hospitalization or death occurred in 69 (0.55%) patients who were prescribed nirmatrelvir plus ritonavir and 310 (0.97%) who were not (adjusted risk ratio, 0.56 [95% CI, 0.42 to 0.75]). Recipients of nirmatrelvir plus ritonavir had lower risk for hospitalization (adjusted risk ratio, 0.60 [CI, 0.44 to 0.81]) and death (adjusted risk ratio, 0.29 [CI, 0.12 to 0.71]). Limitation: Potential residual confounding due to differential access to COVID-19 vaccines, diagnostic tests, and treatment.
Conclusion: The overall risk for hospitalization or death was already low (1%) after an outpatient diagnosis of COVID-19, but nirmatrelvir plus ritonavir reduced this risk further.
Author contributions are available at Annals.org. Previous Posting: This manuscript was posted as a preprint on medRxiv on 17 June 2022. doi:10.1101/2022.06. 14.22276393
References
Administrative, Kim, Lennes, Patel, Gainer et al., logistic support
Arbel, Sagy, Hoshen, Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge, N Engl J Med,
doi:10.1056/NEJMoa2204919Bar-On, Goldberg, Mandel, Protection of BNT162b2 vaccine booster against Covid-19 in Israel, N Engl J Med,
doi:10.1056/NEJMoa2114255Cole, Hernán, Constructing inverse probability weights for marginal structural models, Am J Epidemiol,
doi:10.1093/aje/kwn164Denz, Klaaßen-Mielke, Timmesfeld, Boucau, Uddin et al., Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19. medRxiv,
doi:10.1101/2022.05.24.22275326Dryden-Peterson, Kim, Caniglia, Patel, Dutton et al., ORIGINAL RESEARCH Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System Author Contributions: Conception and design
Ganatra, Dani, Ahmad, Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with Covid-19, Clin Infect Dis,
doi:10.1093/cid/ciac673Ganesh, Philpot, Bierle, Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019, J Infect Dis,
doi:10.1093/infdis/jiab377Hammond, Leister-Tebbe, Gardner, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542House, National COVID-19 Preparedness Plan
House, National COVID-19 Preparedness Plan
Kind, Jencks, Brock, Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study, Ann Intern Med,
doi:10.7326/M13-2946Lambrou, Shirk, Steele, Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants-United States, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7106a4Liang, Zeger, Cole, Hernán, Longitudinal data analysis using generalized linear models, Comput Methods Programs Biomed,
doi:10.1093/biomet/73.1.13O'horo, Challener, Speicher, Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the Delta variant, Mayo Clin Proc,
doi:10.1056/NEJMp1802313Zou, A modified Poisson regression approach to prospective studies with binary data, Am J Epidemiol
{ 'indexed': { 'date-parts': [[2022, 12, 12]],
'date-time': '2022-12-12T22:41:33Z',
'timestamp': 1670884893614},
'reference-count': 16,
'publisher': 'American College of Physicians',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'DOI': '10.7326/m22-2141',
'type': 'journal-article',
'created': { 'date-parts': [[2022, 12, 12]],
'date-time': '2022-12-12T22:00:19Z',
'timestamp': 1670882419000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System',
'prefix': '10.7326',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-8487-9731',
'authenticated-orcid': False,
'given': 'Scott',
'family': 'Dryden-Peterson',
'sequence': 'first',
'affiliation': [ { 'name': "Brigham and Women's Hospital and Harvard T.H. Chan School of "
'Public Health, Boston, Massachusetts, and Botswana Harvard AIDS '
'Institute, Gaborone, Botswana (S.D.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-6551-2881',
'authenticated-orcid': False,
'given': 'Andy',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': "Brigham and Women's Hospital, Boston, Massachusetts (A.K., L.D., "
'E.D., L.R.B., A.E.W.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-4712-2657',
'authenticated-orcid': False,
'given': 'Arthur Y.',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Massachusetts General Hospital, Boston, Massachusetts (A.Y.K., '
'I.T.L., R.T.G.)'}]},
{ 'given': 'Ellen C.',
'family': 'Caniglia',
'sequence': 'additional',
'affiliation': [ { 'name': 'Perelman School of Medicine, University of Pennsylvania, '
'Philadelphia, Pennsylvania (E.C.C.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-0783-3411',
'authenticated-orcid': False,
'given': 'Inga T.',
'family': 'Lennes',
'sequence': 'additional',
'affiliation': [ { 'name': 'Massachusetts General Hospital, Boston, Massachusetts (A.Y.K., '
'I.T.L., R.T.G.)'}]},
{ 'given': 'Rajesh',
'family': 'Patel',
'sequence': 'additional',
'affiliation': [{'name': 'Beth Israel Lahey Health, Cambridge, Massachusetts (R.P.)'}]},
{ 'given': 'Lindsay',
'family': 'Gainer',
'sequence': 'additional',
'affiliation': [ { 'name': 'Mass General Brigham Integrated Care, Somerville, Massachusetts '
'(L.G.).'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-1174-0760',
'authenticated-orcid': False,
'given': 'Lisa',
'family': 'Dutton',
'sequence': 'additional',
'affiliation': [ { 'name': "Brigham and Women's Hospital, Boston, Massachusetts (A.K., L.D., "
'E.D., L.R.B., A.E.W.)'}]},
{ 'given': 'Elizabeth',
'family': 'Donahue',
'sequence': 'additional',
'affiliation': [ { 'name': "Brigham and Women's Hospital, Boston, Massachusetts (A.K., L.D., "
'E.D., L.R.B., A.E.W.)'}]},
{ 'given': 'Rajesh T.',
'family': 'Gandhi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Massachusetts General Hospital, Boston, Massachusetts (A.Y.K., '
'I.T.L., R.T.G.)'}]},
{ 'given': 'Lindsey R.',
'family': 'Baden',
'sequence': 'additional',
'affiliation': [ { 'name': "Brigham and Women's Hospital, Boston, Massachusetts (A.K., L.D., "
'E.D., L.R.B., A.E.W.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-2810-1618',
'authenticated-orcid': False,
'given': 'Ann E.',
'family': 'Woolley',
'sequence': 'additional',
'affiliation': [ { 'name': "Brigham and Women's Hospital, Boston, Massachusetts (A.K., L.D., "
'E.D., L.R.B., A.E.W.)'}]}],
'member': '4285',
'published-online': {'date-parts': [[2022, 12, 13]]},
'reference': [ {'key': 'r1-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2118542'},
{'key': 'r5-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2204919'},
{'key': 'r6-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciac673'},
{'key': 'r7-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm7106a4'},
{'key': 'r8-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiab377'},
{'key': 'r9-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.mayocp.2021.12.002'},
{'key': 'r10-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMp1802313'},
{'key': 'r11-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M13-2946'},
{'key': 'r12-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2114255'},
{'key': 'r13-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/aje/kwn164'},
{'key': 'r14-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/aje/kwh090'},
{ 'key': 'r15-M222141',
'doi-asserted-by': 'crossref',
'unstructured': 'Højsgaard S, Halekoh U, Yan J. The R package geepack for generalized '
'estimating equations. J Stat Softw. 2005;15:1-11. '
'doi:10.18637/jss.v015.i02',
'DOI': '10.18637/jss.v015.i02'},
{ 'key': 'r16-M222141',
'doi-asserted-by': 'crossref',
'unstructured': 'Liang KY, Zeger SL. Longitudinal data analysis using generalized linear '
'models. Biometrika. 1986;73:13-22. doi:10.1093/biomet/73.1.13',
'DOI': '10.1093/biomet/73.1.13'},
{'key': 'r17-M222141', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cmpb.2003.10.004'},
{ 'key': 'r18-M222141',
'unstructured': 'Denz R, Klaaßen-Mielke R, Timmesfeld N. A comparison of different '
'methods to adjust survival curves for confounders. arXiv. Preprint '
'posted online 18 March 2022. doi:10.48550/arXiv.2203.10002'},
{ 'key': 'r19-M222141',
'doi-asserted-by': 'crossref',
'unstructured': 'Boucau J, Uddin R, Marino C, et al. Virologic characterization of '
'symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19. '
'medRxiv. Preprint posted online 26 May 2022. '
'doi:10.1101/2022.05.24.22275326',
'DOI': '10.1101/2022.05.24.22275326'}],
'container-title': 'Annals of Internal Medicine',
'original-title': [],
'language': 'en',
'deposited': { 'date-parts': [[2022, 12, 12]],
'date-time': '2022-12-12T22:00:41Z',
'timestamp': 1670882441000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.acpjournals.org/doi/10.7326/M22-2141'}},
'subtitle': ['A Population-Based Cohort Study'],
'short-title': [],
'issued': {'date-parts': [[2022, 12, 13]]},
'references-count': 16,
'alternative-id': ['10.7326/M22-2141'],
'URL': 'http://dx.doi.org/10.7326/M22-2141',
'relation': {},
'ISSN': ['0003-4819', '1539-3704'],
'subject': ['General Medicine', 'Internal Medicine'],
'container-title-short': 'Ann Intern Med',
'published': {'date-parts': [[2022, 12, 13]]}}
